Anew Medical, Inc.
Anew Medical, Inc. (WENAW) Stock Overview
Explore Anew Medical, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
681.4K
P/E Ratio
-0.21
EPS (TTM)
N/A
ROE
-0.54%
WENAW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Anew Medical, Inc. (WENAW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.04.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.21 and a market capitalization of 681.4K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Anew Medical, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. Anew Medical, Inc. is based in Omaha, Nebraska.
Joseph Sinkule
1
13576 Walnut Street, Omaha, NE
1970